The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy

Area of Science:

• Molecular Biology
• Cancer Biology
• Drug Discovery

Background:

• The p53 gene is a critical tumor suppressor involved in cell cycle regulation, DNA repair, differentiation, and apoptosis.
• MDM2 and MDMX proteins regulate p53 activity through binding interactions, influencing cell proliferation and apoptosis.
• MDM2 mediates p53 degradation, while MDMX inhibits p53 transcriptional activity.

Purpose of the Study:

• To review the structural features, biological functions, and mechanisms of the p53-MDM2/MDMX interaction.
• To summarize the development of small-molecule inhibitors targeting the p53-MDM2/MDMX pathway for anti-tumor therapy.

Main Methods:

• Literature review of structural biology, molecular mechanisms, and preclinical studies.
• Analysis of small-molecule inhibitors designed to disrupt p53-MDM2 and p53-MDMX interactions.

Main Results:

• Detailed structural and functional insights into the p53-MDM2/MDMX complex.
• Identification of small molecules that inhibit MDM2/MDMX binding to p53, thereby restoring p53 tumor suppressor functions.
• Demonstration of anti-tumor effects through modulation of the p53 pathway.

Conclusions:

• Targeting the p53-MDM2/MDMX interaction with small molecules represents a promising therapeutic strategy for cancer treatment.
• Restoring p53 activity by inhibiting MDM2/MDMX binding offers a viable approach to reactivate tumor suppression in cancer cells.